Wordt geladen...
OR20-5 28-Day Dosing with Avexitide Improves Hyperinsulinemic Hypoglycemia in Patients with Severe, Refractory Post-Bariatric Hypoglycemia: The PREVENT Study
Avexitide (formerly exendin 9-39) is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist in development as a liquid formulation for subcutaneous (SC) injection for treatment of post-bariatric hypoglycemia (PBH). PBH, a rare disease with high unmet medical need and no approved pharma...
Bewaard in:
| Gepubliceerd in: | J Endocr Soc |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Endocrine Society
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6554793/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR20-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|